126 related articles for article (PubMed ID: 9492224)
1. Synthesis of monomeric and polymeric conjugates carrying a thrombin inhibitor through an ester bond.
Noguchi H; Iwata H; Ikada Y
J Biomed Mater Res; 1998 Mar; 39(4):621-9. PubMed ID: 9492224
[TBL] [Abstract][Full Text] [Related]
2. A short synthesis of argatroban. a potent selective thrombin inhibitor.
Cossy J; Belotti D
Bioorg Med Chem Lett; 2001 Aug; 11(15):1989-92. PubMed ID: 11454464
[TBL] [Abstract][Full Text] [Related]
3. Argatroban and inhibition of the vasomotor actions of thrombin.
Winn MJ; Jain K; Ku DD
J Cardiovasc Pharmacol; 1993 Nov; 22(5):754-60. PubMed ID: 7506329
[TBL] [Abstract][Full Text] [Related]
4. Selective inhibition of thrombin by (2R,4R)-4-methyl-1-[N2-[(3-methyl-1,2,3,4-tetrahydro-8-quinolinyl++ +) sulfonyl]-l-arginyl)]-2-piperidinecarboxylic acid.
Kikumoto R; Tamao Y; Tezuka T; Tonomura S; Hara H; Ninomiya K; Hijikata A; Okamoto S
Biochemistry; 1984 Jan; 23(1):85-90. PubMed ID: 6691968
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and nonthrombogenicity of polymer membrane with surface-graft polymers carrying thrombin inhibitor.
Ito Y; Liu LS; Matsuo R; Imanishi Y
J Biomed Mater Res; 1992 Aug; 26(8):1065-80. PubMed ID: 1429756
[TBL] [Abstract][Full Text] [Related]
6. In vivo thrombin inhibition enhances and sustains arterial recanalization with recombinant tissue-type plasminogen activator.
Jang IK; Gold HK; Leinbach RC; Fallon JT; Collen D
Circ Res; 1990 Dec; 67(6):1552-61. PubMed ID: 2123135
[TBL] [Abstract][Full Text] [Related]
7. Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation.
Warkentin TE; Greinacher A; Craven S; Dewar L; Sheppard JA; Ofosu FA
Thromb Haemost; 2005 Nov; 94(5):958-64. PubMed ID: 16363236
[TBL] [Abstract][Full Text] [Related]
8. Combined administration of aspirin and a specific thrombin inhibitor in man.
Clarke RJ; Mayo G; FitzGerald GA; Fitzgerald DJ
Circulation; 1991 May; 83(5):1510-8. PubMed ID: 2022012
[TBL] [Abstract][Full Text] [Related]
9. Argatroban, specific thrombin inhibitor, induced phenotype change of cultured rabbit vascular smooth muscle cells.
Yoshinaga M; Sunagawa M; Shimada S; Nakamura M; Murayama S; Kosugi T
Eur J Pharmacol; 2003 Feb; 461(1):9-17. PubMed ID: 12568910
[TBL] [Abstract][Full Text] [Related]
10. The antithrombotic effect of low molecular weight synthetic thrombin inhibitors, argatroban and PPACK, on He-Ne laser-induced thrombosis in rat mesenteric microvessels.
Yamashita T; Yamamoto J; Sasaki Y; Matsuoka A
Thromb Res; 1993 Jan; 69(1):93-100. PubMed ID: 8465278
[TBL] [Abstract][Full Text] [Related]
11. Geometry of binding of the benzamidine- and arginine-based inhibitors N alpha-(2-naphthyl-sulphonyl-glycyl)-DL-p-amidinophenylalanyl-pipe ridine (NAPAP) and (2R,4R)-4-methyl-1-[N alpha-(3-methyl-1,2,3,4-tetrahydro-8- quinolinesulphonyl)-L-arginyl]-2-piperidine carboxylic acid (MQPA) to human alpha-thrombin. X-ray crystallographic determination of the NAPAP-trypsin complex and modeling of NAPAP-thrombin and MQPA-thrombin.
Bode W; Turk D; Stürzebecher J
Eur J Biochem; 1990 Oct; 193(1):175-82. PubMed ID: 2226434
[TBL] [Abstract][Full Text] [Related]
12. Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition.
Jang IK; Gold HK; Ziskind AA; Leinbach RC; Fallon JT; Collen D
Circulation; 1990 Jan; 81(1):219-25. PubMed ID: 2297828
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of anticoagulant effects of direct thrombin inhibitors, dabigatran and argatroban, based on the Lineweaver-Burk plot applied to the Clauss assay.
Fujimori Y; Wakui M; Katagiri H; Ohira K; Shimizu N; Murata M
J Clin Pathol; 2016 Apr; 69(4):370-2. PubMed ID: 26754829
[No Abstract] [Full Text] [Related]
14. Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris.
Gold HK; Torres FW; Garabedian HD; Werner W; Jang IK; Khan A; Hagstrom JN; Yasuda T; Leinbach RC; Newell JB
J Am Coll Cardiol; 1993 Apr; 21(5):1039-47. PubMed ID: 8459055
[TBL] [Abstract][Full Text] [Related]
15. Anticoagulation with argatroban for elective percutaneous coronary intervention: population pharmacokinetics and pharmacokinetic-pharmacodynamic relationship of coagulation parameters.
Akimoto K; Klinkhardt U; Zeiher A; Niethammer M; Harder S
J Clin Pharmacol; 2011 Jun; 51(6):805-18. PubMed ID: 20663996
[TBL] [Abstract][Full Text] [Related]
16. Ecarin modified rotational thrombelastometry: a point-of-care applicable alternative to monitor the direct thrombin inhibitor argatroban.
Schaden E; Schober A; Hacker S; Kozek-Langenecker S
Wien Klin Wochenschr; 2013 Mar; 125(5-6):156-9. PubMed ID: 23440521
[TBL] [Abstract][Full Text] [Related]
17. Determination of inhibitory potency of argatroban toward thrombin by electrophoretically mediated microanalysis.
Pochet L; Servais AC; Farcas E; Bettonville V; Bouckaert C; Fillet M
Talanta; 2013 Nov; 116():719-25. PubMed ID: 24148466
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and Biological Evaluation of Some New 2,5-Substituted 1-Ethyl-1H-benzoimidazole Fluorinated Derivatives as Direct Thrombin Inhibitors.
Li M; Ren Y
Arch Pharm (Weinheim); 2015 May; 348(5):353-65. PubMed ID: 25824648
[TBL] [Abstract][Full Text] [Related]
19. [Experimental and clinical results with the thrombin inhibitor Argatroban].
Breddin HK
Hamostaseologie; 2002 Aug; 22(3):55-9. PubMed ID: 12215762
[TBL] [Abstract][Full Text] [Related]
20. Argatroban more effectively inhibits the thrombin activity in synovial fluid than naturally occurring thrombin inhibitors.
Asanuma K; Yoshikawa T; Yoshida K; Okamoto T; Asanuma Y; Hayashi T; Akita N; Oi T; Nishimura A; Hasegawa M; Sudo A
Cell Mol Biol (Noisy-le-grand); 2016 May; 62(6):27-32. PubMed ID: 27262798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
